Comparative behavioural profile of newer antianxiety drugs on different mazes.

Anxiety is associated with diverse range of psychiatric conditions. In the present study, antianxiety effect of fluoxetine, citalopram (SSRI's), gabapentin (antiepileptic drugs), venlafaxine (SNRI), clozapine and resperidone (atypical antipsychotics) and a herbal preparation ashwagandha on elevated zero maze and elevated plus maze paradigms was examined. Anti-anxiety potentials of these drugs were compared with diazepam. The drugs tested i.e. fluoxetine (10 mg/kg), citalopram (10 mg/kg), clozapine (0.25, 0.5, 1 mg/kg), resperidone.(0.5, 1 mg/kg), venlafaxine (4, 8, 16 mg/kg), citalopram (10 mg/kg), fluoxetine (10 mg/kg), gabapentin (10, 20 mg/kg) and ashwagandha (100, 200 mg/kg) significantly increased the number of open arm entries and time spent in open arm. These drugs also decreased the latency to enter in open arm as compared to control in both the paradigms. Present study confirms the antianxiety activity of different newer classes of drugs and found some of them comparable to diazepam in both the elevated zero maze and elevated plus maze paradigm.

[1]  Mauro V. Mendlowicz,et al.  Antipsicóticos, anticonvulsivantes, antiadrenérgicos e outras drogas: o que fazer quando o transtorno do estresse pós-traumático não responde aos inibidores seletivos da recaptação da serotonina? , 2007 .

[2]  S. Kulkarni,et al.  Elevated zero maze: a paradigm to evaluate antianxiety effects of drugs. , 2007, Methods and findings in experimental and clinical pharmacology.

[3]  S. Kulkarni,et al.  Involvement of adenosinergic receptors in anxiety related behaviours. , 2007, Indian journal of experimental biology.

[4]  Leonardo Franklin Fontenelle,et al.  [Antipsychotics, anticonvulsants, antiadrenergics and other drugs: what to do when posttraumatic stress disorder does not respond to selective serotonin reuptake inhibitors?]. , 2007, Revista brasileira de psiquiatria.

[5]  T. Schwartz,et al.  Tiagabine in anxiety disorders , 2006, Expert opinion on pharmacotherapy.

[6]  P. Roy-Byrne,et al.  The GABA-benzodiazepine receptor complex: structure, function, and role in anxiety. , 2005, The Journal of clinical psychiatry.

[7]  C. Dourish,et al.  Behavioural and pharmacological characterisation of the elevated “zero-maze” as an animal model of anxiety , 1994, Psychopharmacology.

[8]  T. Schwartz,et al.  History repeats itself: pharmacodynamic trends in the treatment of anxiety disorders. , 2005, Current pharmaceutical design.

[9]  K. Miczek,et al.  Anxiolytic-Like Effects of Escitalopram, Citalopram, and R-Citalopram in Maternally Separated Mouse Pups , 2004, Journal of Pharmacology and Experimental Therapeutics.

[10]  Alka Aneja,et al.  Pharmacology and Therapeutics of Gabapentin in the Treatment of Psychiatric Disorders; Present and Future Perspectives , 2003 .

[11]  S. Brannan,et al.  Olanzapine treatment for post-traumatic stress disorder: an open-label study , 2001, International clinical psychopharmacology.

[12]  S. Bhattacharya,et al.  Anxiolytic-antidepressant activity of Withania somnifera glycowithanolides: an experimental study. , 2000, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[13]  H. Westenberg,et al.  Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors , 2000, Acta psychiatrica Scandinavica. Supplementum.

[14]  M. Pollack,et al.  Placebo-controlled study of gabapentin treatment of panic disorder. , 2000, Journal of clinical psychopharmacology.

[15]  J. Davidson,et al.  Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. , 1999, The Journal of clinical psychiatry.

[16]  F. Goodwin,et al.  Gabapentin treatment of mood disorders: a preliminary study. , 1998, The Journal of clinical psychiatry.

[17]  M. Pollack,et al.  Gabapentin as a potential treatment for anxiety disorders. , 1998, The American journal of psychiatry.

[18]  J. Kocsis,et al.  A summary of mechanistic hypotheses of gabapentin pharmacology , 1998, Epilepsy Research.